A study, published in JAMA Network Open, highlightedß the potential utility of prognostic biomarkers in T1 colorectal cancer (CRC) treatment selection.1
Researchers found that endoscopic therapy (ET) was the most effective strategy for patients with T1 CRC with less aggressive biomarker profiles. However, for patients with more aggressive profiles, laparoscopic colectomy (LC) was more effective but was also costly, making ET the cost-effective option.
“Choice of therapy in class 0 or 4, which have a worse prognosis, may be dependent on patients’ long-term health outcomes, such as recurrent cancer rates and mortality rates, thus requiring further study,” the authors wrote. “Future prospective studies with adequate patient numbers and follow-up duration are needed to better define and validate targeted treatment approaches in T1 CRC based on tumor biomarker profiles.”